drugset / Trial / NCT00283712

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and Crohn's disease. This study will determine if infliximab given in combination with prednisone is a safe and effective treatment for adults with PV.

Timeline

Start
2006-03
Primary completion
2010-12
Completion
2011-03

Outcome

Missed primary endpoint

registry p = 1.00; Risk Difference (RD) 0.00 (90% CI -0.22 to 0.22); Fisher Exact NCT00283712 ↗

paper IFX therapy was not shown to be effective for the treatment of patients with PV in this randomized, placebo-controlled trial PMID 25123295 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications